Pazopanib is an oral receptor tyrosine kinase inhibitor approved for treatment of patients with advanced renal cell carcinoma and soft tissue sarcoma40, 41 targeting vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor β (PDGFRβ) and c-Kit.42 We confirmed the screening results (Supplementary Figures 1b–e) and performed dose–response curves to quantitatively assess the inhibitory potency of the two drugs. The gene discussed is FLT1; the disease is renal cell carcinoma.